Squarepoint
OVID icon

Squarepoint’s Ovid Therapeutics OVID Stock Holding History

Squarepoint’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$50.9K Sell
18,937
-179,034
-90% -$462K ﹤0.01% 4268
2026
Q1 		$439K Buy
197,971
+158,937
+407% +$284K ﹤0.01% 3408
2025
Q4 		$63.6K Sell
39,034
-75,889
-66% -$117K ﹤0.01% 4105
2025
Q3 		$149K Sell
114,923
-106,203
-48% -$92K ﹤0.01% 4026
2025
Q2 		$72.9K Sell
221,126
-44,365
-17% -$13.4K ﹤0.01% 4245
2025
Q1 		$82.8K Buy
+265,491
New +$163K ﹤0.01% 4268
2024
Q2 		– Sell
-68,343
Closed -$208K – 4497
2024
Q1 		$208K Buy
68,343
+56,962
+501% +$191K ﹤0.01% 3593
2023
Q4 		$36.6K Buy
+11,381
New +$38.9K ﹤0.01% 3876
2023
Q2 		– Sell
-11,271
Closed -$29.1K – 3884
2023
Q1 		$29.1K Buy
+11,271
New +$26.7K ﹤0.01% 3103
2022
Q3 		– Sell
-10,543
Closed -$23K – 3311
2022
Q2 		$23K Buy
+10,543
New +$25.5K ﹤0.01% 2766
2021
Q3 		– Sell
-37,797
Closed -$148K – 3288
2021
Q2 		$148K Buy
+37,797
New +$149K ﹤0.01% 2932
2021
Q1 		– Sell
-70,987
Closed -$164K – 3490
2020
Q4 		$164K Sell
70,987
-69,731
-50% -$325K ﹤0.01% 2586
2020
Q3 		$808K Buy
+140,718
New +$942K 0.01% 1104
2020
Q2 		– Sell
-11,553
Closed -$34K – 2441
2020
Q1 		$34K Sell
11,553
-14,476
-56% -$48.8K ﹤0.01% 1749
2019
Q4 		$108K Buy
+26,029
New +$82.2K ﹤0.01% 2334
2018
Q3 		– Sell
-14,700
Closed -$115K – 2157
2018
Q2 		$115K Buy
+14,700
New +$126K ﹤0.01% 1630

Other funds holding OVID

JT
Jupiter Topco New York $245B AUM
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Squarepoint's OVID Position: Q2 2026 in Review

Squarepoint reduced its Ovid Therapeutics (OVID) stake by 90% in Q2 2026, selling an estimated $462K and leaving 18,937 shares worth $50.9K. The position accounts for ﹤0.01% of the portfolio, ranked #4268.

Squarepoint first reported a position in OVID in Q2 2018 and has held it in 16 quarters since. The position peaked at $808K in Q3 2020. 131 funds tracked by Wall St. Rank hold OVID as of Q2 2026.

  • Squarepoint held 18,937 shares of Ovid Therapeutics worth $50.9K as of Q2 2026.
  • Squarepoint sold 179,034 Ovid Therapeutics shares in Q2 2026, an estimated $462K.
  • Ovid Therapeutics made up ﹤0.01% of Squarepoint's portfolio in Q2 2026, its #4268 holding.
  • Squarepoint first reported a position in Ovid Therapeutics in Q2 2018 and has held it in 16 quarters since.
  • Squarepoint's Ovid Therapeutics position peaked at $808K in Q3 2020.
  • 131 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.